Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 16/20 | 0.58 |
| ▸ | MMP2 | P08253 | 15/20 | 0.58 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.50 |
| ▸ | MMP3 | P08254 | 3/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 2/20 | 0.46 |
| ▸ | MMP8 | P22894 | 2/20 | 0.46 |
| ▸ | MMP14 | P50281 | 2/20 | 0.46 |
| ▸ | MMP25 | Q9NPA2 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12245543 | 1.00 | MMP9 (0.58) | MMP9MMP2ADAM17MMP3MMP13 | |
| SCHEMBL15849271 | 0.92 | MMP9 (0.62) | MMP9MMP2ADAM17MMP3MMP13 | |
| SCHEMBL15849272 | 0.92 | MMP9 (0.62) | MMP9MMP2ADAM17MMP3MMP13 | |
| SCHEMBL12246386 | 0.91 | MMP9 (0.60) | MMP9MMP2ADAM17MMP3MMP13 | |
| SCHEMBL12244633 | 0.91 | MMP9 (0.60) | MMP9MMP2ADAM17MMP3MMP13 | |
| SCHEMBL13272370 | 0.90 | MMP9 (0.71) | MMP9MMP2ADAM17MMP3MMP13 | |
| SCHEMBL15849270 | 0.90 | MMP9 (0.71) | MMP9MMP2ADAM17MMP3MMP13 | |
| SCHEMBL15849301 | 0.90 | MMP9 (0.50) | MMP9MMP2ADAM17MMP3MMP13 | |
| SCHEMBL15849295 | 0.90 | MMP9 (0.50) | MMP9MMP2ADAM17MMP3MMP13 | |
| SCHEMBL15849287 | 0.88 | MMP9 (0.52) | MMP9MMP2ADAM17MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382206-B1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISEASES | AQUILUS PHARMACEUTICALS INC (US) | 2016-03-23 | — | — | EP | disclosed |
| US-8765953-B2 | Compounds and methods for the treatment of pain and other diseases | AQUILUS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110257222-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISEASES | AQUILUS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257222-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISEASES | MMP3, MMP9, MMP10 | MMP9 2/4885MMP2 11/4885ADAM17 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.